Lymphoma, Large B-Cell, Diffuse
"Lymphoma, Large B-Cell, Diffuse" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Descriptor ID |
D016403
|
MeSH Number(s) |
C04.557.386.480.150.585 C15.604.515.569.480.150.585 C20.683.515.761.480.150.585
|
Concept/Terms |
Lymphoma, Large B-Cell, Diffuse- Lymphoma, Large B-Cell, Diffuse
- Diffuse Large-Cell Lymphoma
- Diffuse Large Cell Lymphoma
- Diffuse Large-Cell Lymphomas
- Large-Cell Lymphomas, Diffuse
- Lymphomas, Diffuse Large-Cell
- Diffuse, Large B-Cell, Lymphoma
- Histiocytic Lymphoma
- Histiocytic Lymphomas
- Lymphomas, Histiocytic
- Histiocytic Lymphoma, Diffuse
- Diffuse Histiocytic Lymphoma
- Diffuse Histiocytic Lymphomas
- Histiocytic Lymphomas, Diffuse
- Lymphoma, Diffuse Histiocytic
- Lymphomas, Diffuse Histiocytic
- Large Lymphoid Lymphoma, Diffuse
- Lymphoma, Large-Cell
- Large-Cell Lymphomas
- Lymphoma, Large Cell
- Lymphomas, Large-Cell
- Large-Cell Lymphoma, Diffuse
- Large Cell Lymphoma, Diffuse
- Lymphoma, Diffuse Large-Cell
- Lymphoma, Diffuse Large Cell
- Lymphoma, Histiocytic
- Lymphoma, Histiocytic, Diffuse
- Lymphoma, Large Cell, Diffuse
- Lymphoma, Large Lymphoid, Diffuse
- Lymphoma, Large-Cell, Diffuse
- Large-Cell Lymphoma
- Large Cell Lymphoma
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Large B-Cell, Diffuse".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, B-Cell [C04.557.386.480.150]
- Lymphoma, Large B-Cell, Diffuse [C04.557.386.480.150.585]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, B-Cell [C15.604.515.569.480.150]
- Lymphoma, Large B-Cell, Diffuse [C15.604.515.569.480.150.585]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, B-Cell [C20.683.515.761.480.150]
- Lymphoma, Large B-Cell, Diffuse [C20.683.515.761.480.150.585]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Large B-Cell, Diffuse".
This graph shows the total number of publications written about "Lymphoma, Large B-Cell, Diffuse" by people in this website by year, and whether "Lymphoma, Large B-Cell, Diffuse" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1980 | 2 | 0 | 2 | 1981 | 1 | 0 | 1 | 1982 | 1 | 0 | 1 | 1985 | 1 | 0 | 1 | 1987 | 1 | 0 | 1 | 1989 | 1 | 0 | 1 | 1991 | 3 | 0 | 3 | 1996 | 3 | 0 | 3 | 1997 | 0 | 1 | 1 | 1998 | 3 | 0 | 3 | 1999 | 1 | 0 | 1 | 2000 | 1 | 0 | 1 | 2001 | 3 | 1 | 4 | 2002 | 1 | 0 | 1 | 2003 | 2 | 0 | 2 | 2004 | 0 | 1 | 1 | 2006 | 0 | 1 | 1 | 2007 | 2 | 0 | 2 | 2008 | 3 | 1 | 4 | 2009 | 4 | 2 | 6 | 2010 | 0 | 1 | 1 | 2011 | 3 | 2 | 5 | 2012 | 4 | 0 | 4 | 2013 | 2 | 0 | 2 | 2014 | 4 | 1 | 5 | 2015 | 3 | 0 | 3 | 2016 | 6 | 1 | 7 | 2017 | 4 | 0 | 4 | 2018 | 1 | 1 | 2 | 2019 | 7 | 2 | 9 | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, Large B-Cell, Diffuse" by people in Profiles.
-
Song JY, Egan C, Bouska AC, Zhang W, Gong Q, Venkataraman G, Herrera AF, Chen L, Ottesen R, Niland JC, Bedell V, Valle-Catuna M, Murata-Collins J, Weisenburger DD, Iqbal J, Jaffe ES, Chan WC. Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma. Leukemia. 2020 08; 34(8):2238-2242.
-
Nguyen K, Kim G, Chiu M. Eccrine poromatosis following chemotherapy and radiation therapy. Dermatol Online J. 2019 Nov 15; 25(11).
-
Guadamuz JS, Ozenberger K, Qato DM, Ko NY, Saffore CD, Adimadhyam S, Cha AS, Moran KM, Sweiss K, Patel PR, Chiu BC, Calip GS. Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults. Medicine (Baltimore). 2019 Nov; 98(46):e17960.
-
Chiu BC, Zhang Z, You Q, Zeng C, Stepniak E, Bracci PM, Yu K, Venkataraman G, Smith SM, He C, Zhang W. Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma. Blood Adv. 2019 10 08; 3(19):2790-2799.
-
Allan JN, Van Besien K. It's not all about the CNS. High dose methotrexate in DLBCL. Leuk Lymphoma. 2019 08; 60(8):1845-1847.
-
Parker K, Venkataraman G. Challenges in the Diagnosis of Gray Zone Lymphomas. Surg Pathol Clin. 2019 Sep; 12(3):709-718.
-
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019 07 20; 37(21):1790-1799.
-
Godfrey J, Tumuluru S, Bao R, Leukam M, Venkataraman G, Phillip J, Fitzpatrick C, McElherne J, MacNabb BW, Orlowski R, Smith SM, Kline J. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 2019 05 23; 133(21):2279-2290.
-
Kezlarian B, Alhyari M, Venkataraman G, Karner K, Inamdar KV, Menon MP. GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities. Appl Immunohistochem Mol Morphol. 2019 03; 27(3):180-184.
-
Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|